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Abstract
Background: Streptococcus pneumoniae serotype 5 is among the most common serotypes causing invasive
pneumococcal disease (IPD) in The Gambia. We anticipate that introduction of the 13-valent pneumococcal
conjugate vaccine (PCV-13) into routine vaccination in The Gambia will reduce serotype 5 IPD. However, the
emergence of new clones that have altered their genetic repertoire through capsular switching or genetic
recombination after vaccination with PCV-13 poses a threat to this public health effort. In order to monitor for
potential genetic changes post-PCV-13 vaccination, we established the baseline population structure, epidemiology,
and antibiotic resistance patterns of serotype 5 before the introduction of PCV-13.
Methods: Fifty-five invasive S. pneumoniae serotype 5 isolates were recovered from January 2009 to August 2011 in
a population-based study in the Upper River Region of The Gambia. Serotyping was done by latex agglutination
and confirmed by serotype-specific Polymerase Chain Reaction (PCR). Genotyping was undertaken using Multilocus
Sequence Typing (MLST). Antimicrobial sensitivity was done using disc diffusion. Contingency table analyses were
conducted using Pearson’s Chi2 and Fisher’s exact test. Clustering was performed using Bionumerics version 6.5.
Results: MLST resolved S. pneumoniae serotype 5 isolates into 3 sequence types (ST), namely ST 289(6/55), ST
3339(19/55) and ST 3404(30/55). ST 289 was identified as the major clonal complex. ST 3339, the prevalent
genotype in 2009 [84.6 % (11/13)], was replaced by ST 3404 [70.4 % (19/27)] in 2010 as the dominant ST.
Interestingly, ST 3404 showed lower resistance to tetracycline and oxacillin (P < 0.001), an empirical surrogate to
penicillin in The Gambia.
Conclusions: There has been an emergence of ST 3404 in The Gambia prior to the introduction of PCV-13. Our
findings provide important background data for future assessment of the impact of PCV-13 into routine
immunization in developing countries, such as The Gambia.
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Background
Streptococcus pneumoniae is a Gram positive bacterium
that colonizes the upper respiratory tract of humans and
is capable of causing life-threatening infections, particu-
larly among immunosuppressed individuals [1, 2]. S. pneu-
moniae has a circular genome containing between 2
million to 2.1 million base pairs [2]. Two-thirds of its
2236 open reading frames have been assigned roles based
on their predicted gene products [2, 3]. Conserved
proteins with unknown functions constitute 16 % of S.
pneumoniae’s open reading frames, of which, 20 % are
unique to S. pneumoniae [2, 3]. S. pneumoniae has 1553
and 154 genes that are important for viability and viru-
lence, respectively. Genetic information between strains
can vary by up to 10 % [2, 4].
Based on its capsular structure, S. pneumoniae can be
categorized into more than 90 different serotypes which
differ in their infection ability and severity [5, 6]. S.
pneumoniae causes invasive pneumococcal diseases
(IPD) such as septicemia and meningitis, and is the lead-
ing cause of bacterial disease in The Gambia [7]. Carriage
of S. pneumoniae among Gambian children aged less than
1 year is 97 % and 93 % among babies aged less than
1 month [8]. Serotype 5 is one of the most common sero-
types causing IPD in The Gambia [9, 10]. Pneumococcal
diseases in infants and young children can be prevented
by the pneumococcal conjugate vaccine (PCV). Three
PCV vaccines — PCV-7 (7-valent vaccine), PCV-10 (10-
valent vaccine), and PCV-13 (13-valent vaccine) — have
been used in routine immunization in many countries.
Even though IPD in The Gambia is commonly caused by
serotype 5 [5], the 13-valent vaccine containing serotype 5
was only recently introduced in July 2011.
The incidence of IPD due to serotype 5 in Eastern
Gambia in 2008 was estimated to be 7 (95 % CI 0, 38)
per 100 000 person-years in children aged 2–59 months.
Two years later in 2010, the incidence of serotype 5 rose
to 51 (95 % CI 28, 86) per 100 000 person-years [Unpub-
lished data, Grant Mackenzie, October 2011]. Under-
standing whether the introduction of PCV-13 will have an
impact on the population structure, epidemiology and
antibiotic resistance patterns of serotype 5 is important to
scientists, public health practitioners and policy makers.
The introduction of PCV-13 into the routine vaccination
schedule in July 2011 is expected to lead to the reduction
of serotype 5 IPD. However, the possibility of the emer-
gence of new clones through capsular switching or recom-
bination after vaccination is a threat to the public health
impact of the vaccination program. Following introduc-
tion of PCV-7, a study in Canada showed the emergence
of multi-drug resistant (MDR) serotype 19A through re-
combination [10]. The Canadian study painted a complex
genetic picture where vaccine-selection pressure, high-
level drug resistance, and S. pneumoniae mutational
events created a “perfect storm” for the emergence of the
multi-drug-resistant 19A serotype [11]. However, in order
to surveil for potential post-vaccine changes, it is essential
to establish a reference point from which a comparison
could be made. The objective of this study was therefore
to determine the population structure, epidemiology, and
resistance patterns of S. pneumoniae serotype 5 prior to
PCV-13’s introduction in to The Gambia, making available
a reference point to evaluate the impact of PCV-13’s intro-
duction into routine immunization.
Methods
Study area and ethical statement
The Pneumococcal Surveillance Project (PSP), hosted
by the Medical Research Council Unit (MRC) in collabor-
ation with the Gambian government is aimed at evaluat-
ing the effectiveness of the introduction of PCV into The
Gambia. The PSP study area covers the south bank of the
Upper River Region (1111 km2), which has a population
of about 160,000 inhabitants [12]. The surveillance area is
set in the Basse Health and Demographic Surveillance
System, in which the population is enumerated every four
months. The study base is located in the town of Basse.
The study population comprised all cases of pneumonia,
sepsis and meningitis among patients aged 2 weeks and
older in the study area. This study was conducted in ac-
cordance with the Declaration of Helsinki and was ap-
proved by the Gambia Government/MRC Joint Ethics
Committee (EC) — Scientific Coordinating Committee
(SCC) number 1087. Written informed consent was ob-
tained from all study participants.
Isolation and antimicrobial susceptibility testing
Between January 2009 and August 2011, 55 serotype 5
isolates were recovered from 19 female and 24 male in a
population-based study in Eastern Gambia. Isolates were
recovered from either blood, cerebrospinal fluid, or lung
aspirates. A total of 13 isolates were obtained in 2009,
while 27 and 15 were obtained in 2010 and 2011, re-
spectively. More than one isolate was recovered from 11
patients. Ten patients provided 2 isolates each while 1
patient provided 3 isolates. When more than one isolate
was obtained from the same patient they were obtained
at separate time intervals. S. pneumoniae was identified
as previously described [13]. Oxoid antibiotic susceptibil-
ity disc (Thermofisher Scientific, UK) used to test for anti-
microbial susceptibility included co-trimoxazole (25 μg),
chloramphenicol (30 μg), tetracycline (30 μg), erythro-
mycin (15 μg) and oxacillin (1 μg). Colonies of S.
pneumonie from an overnight Mueller-Hinton agar
plate supplemented with 5 % sheep blood (MHBA)
were suspended in 2 ml of Mueller-Hinton broth
(MHB). Tubes containing MHB were briefly vortexed
to achieve a uniform suspension and turbidity was
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adjusted to a 0.5 McFarland standard (Biomerieux SA,
France) equivalent to 1.5 × 10^8 cfu/ml. Sterile cotton tips
were thereafter dipped into the suspensions and streaked
to cover the entire surface of MHBA plates ensuring
even spread. Antimicrobial discs were carefully placed
on plates under antiseptic conditions. Plates were incu-
bated overnight at 37 °C in 5 % CO2. Zones of Inhibition
(ZOI) were measured and interpreted as resistant, inter-
mediate or susceptible, using Clinical Laboratory Standard
Institute (CLSI) break-point, ATCC 49619 was used as a
control [13].
Serotyping
Serotyping was carried out by latex agglutination. Briefly,
for each isolate, a pneumococcal cell suspension was made
in 2 ml normal saline (1.0Macfarland) from an overnight-
incubated (37 °C) BA plate. Twenty microliters of each
cell suspension was dispensed into 10 wells of a serotyping
tray. An equivalent amount of each of the main group
latex antisera (A,B,C,D,E,F,G,H,I and Omni) was added to
the wells. The tray was then gently rocked for about 2 min
and agglutinations observed. Serotype was determined
with the aid of a chart (Statens Serum Institute,
Copenhagen, Denmark). All isolates used for this project
were confirmed using a serotype specific PCR. The Sero-
type 5 specific PCR was performed using primers target-
ing the wzy gene (Table 1). The portion of interest of the
wzy gene was amplified as per a US Centers for Disease
Control protocol [14]. Amplified PCR products were
separated on 2 % agarose gel pre-stained with 0.5 μg/mL
of ethidium bromide. The gel was run at 100 V in 1×
Tris-borate-EDTA (TBE) for 1 h and band patterns
were visualized by UV illumination with a gel docu-
mentation system (Gel Doc 2000; Bio- Rad, UK). Iso-
lates were assigned as serotype 5 if both CpsA and
serotype specific bands were amplified.
Genotyping (MLST)
Genotyping was done by means of Multilocus Sequencing
Typing (MLST). Seven housekeeping genes including aroE
(shikimate dehydrogenase), ddl (D-alanine-D-alanine
ligase), gdh (glucose-6-phosphate dehydrogenase), gki (glu-
cose kinase), recP (transketolase), spi (signal peptidase I)
and xpt (xanthine phosphoribosyltransferase) were targeted
for amplification by PCR. The PCRs were performed in
25 μl volumes per reaction as previously described [15].
Thermal cycling was performed in a Palm cycler (Corbett
research) under the following conditions: 95 °C for 10 min
followed by 30 amplification cycles of 95 °C for 30 s, 55 °C
for 30 s, 72 °C for 1 min, and a final extension at 72 °C for
10 min. Sequencing was done by incorporation of
chain-terminating dideoxynucleotides [16]. A sequencing
reaction was performed for both forward and reverse
strands of each targeted gene (Big Dye Terminator Cycle
Sequencing kit; Applied Biosystems, UK). PCR products
were purified using Qiagen purfication kit (Qiagen Sample
& Assay Technologies, UK) and submitted to the in-house
core sequencing facility in Fajara (Medical Research
Council Unit, The Gambia).
Data analysis
Editing and alignment of sequences for submission to
MLST database [17] for allele and sequence type num-
bers was performed using Laser Gene DNA star, version
7.1. Data was exported into an Excel sheet (Microsoft
2007) for analyses of temporal trends. STATA version 9
(Stata Corporation, College Station, TX, USA) was used
to produce summary data. The Wilcoxon signed ranked
test was used to compare differences in the number of
serotype 5 cases between male and female. In order to
illustrate the differences between various groups with
categorical data, contingency table analyses were
conducted using Pearson’s Chi2 and Fisher’s exact test
(two-sided). Genotype clustering was performed using
Bionumerics version 6.5 (Applied Maths, Saint-Martens-
Latem, Belgium).
Results and discussion
Molecular characterisation
MLST resolved all 55 isolates into 3 sequence types
(ST). ST 3404 [54.5 % (30/55)] was the most prevalent
clone, followed by ST 3339 [34.5 % (19/55)] and ST 289
[11.0 % (6/55)]. In all cases where more than one isolate
was obtained from the same patient, for example from
blood and lung aspirate, no difference in ST was ob-
served, suggesting that the existence of multiple STs
within sterile body fluids is infrequent or non-existent.
Cluster analysis on all serotype 5 isolates in the MLST
Table 1 Oligonucleotide primer sequences used in this study
Primers Primer sequence (5′- 3′) Nucleotide position1 Gene GenBank accession no.
5-f ATA CCT ACA CAA CTT CTG ATT ATG CCT TTG TG 612332 wzy CR931637
5-r GCT CGA TAA ACA TAA TCA ATA TTT GAA AAA GTA TG 645032
cpsA-f GCA GTA CAG CAG TTT GTT GGA CTG ACC 147332 wzg CR931662
cpsA-r GAA TAT TTT CAT TAT CAG TCC CAG TC 160732
1Start position
[32]: Reference
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database showed that both ST 3404 and ST 3339
were unique to Gambia and Senegal (Fig. 1), implying
a recent and local differentiation event. ST 289 was
identified as the major clonal complex in The Gambia
(Fig. 2), this genotype was also widely distributed
worldwide (Fig. 1). However, caution must be exer-
cised when using circle sizes to determine the preva-
lence of a clone (ST), considering that submission of
every IPD allelic profile to the MLST database is not
obligatory.
STs 3339 and 3404 differed from ST289 at two loci,
ddl and spi, respectively. ddl codes for an enzyme in-
volved in cell wall biosynthesis while spi has been associ-
ated with the processing of signal peptides for classical
MHC class I molecules [18, 19]. It would be luring to
infer that the changes in ddl and spi giving rise to clones
ST3339 and ST3404 are of little significance because
they are non-capsular (serotype) changes. For example,
ddl gene diversity has been linked to the recombina-
tional replacement of penicillin binding protein 2b
(pbp2b), a gene located 783 bp upstream of ddl [20].
This linkage suggests that changes in beta-lactam sus-
ceptibility patterns involving pbp2b could be reflected in
ddl diversity. Consequently, observed disparities in ddl
and even spi incidence could potentially be very im-
portant. These findings taken together emphasize the
need for whole genome analysis in order to determine
the relevance of the emergence of ST 3404 and the
prevalence of ST3339 in The Gambia, especially be-
cause both clones originate from a recent and local
differentiation event.
Epidemiology
The median age of patients with invasive disease caused
by serotype 5 was 29 months (lower quartile = 0.8 months,
upper quartile = 240 months). We report no significant
difference between the prevalence of ST3404 or serotype
5 — including all three clones — in male and female pa-
tients. These findings suggest that sex is not a risk factor
as pertains to the acquisition of ST 3404 and of S. pneu-
moniae serotype 5 as a whole. However, these findings are
not unique to serotype 5; the same has been reported
about serotype 1 and most other pneumococcal serotypes
that cause IPD in The Gambia [5].
The number of serotype 5 cases obtained from pa-
tients with IPD varied from year to year, with the
most number of cases reported in between February
and June 2010. The increase in number of serotype 5
in 2010 was correlated with a slight decrease in the
prevalence of ST 3339 and the emergence of ST3404
(Fig. 3). ST 3404 peaked at the beginning of 2010
and has since then been the prevalent ST responsible
for most serotype 5-caused IPD. A number of obser-
vations could be advanced on why ST 3404 has
emerged. For example, it’s plausible to hypothesize
that the introduction of PCV-7 in August 2009 might
have indirectly acted as a selective pressure for the
emergence of the new clone (ST 3404). However, the
unavailability of detailed epidemiological information
which could potentially explain why there is an
increase in incidence of ST 3404 in this study calls
for caution in accounting for the observed trend. Fur-
ther research is needed to explain the observed trend.
Fig. 1 Clustering of STs from diverse world regions by use of the minimum spanning algorithm. Each circle represents an ST. The area of each circle
corresponds to the number of isolates of a given ST in the MLST database. A clonal complex is a group of STs sharing a minimum of 6 out of 7 alleles
[31]. The inferred putative ancestor of all clonal complexes is ST 289. Green portions represent STs found in Gambia including those used for the study
while the other colours represent STs found in the rest of the world
Ashu et al. BMC Infectious Diseases  (2016) 16:33 Page 4 of 7
The most number of serotype 5 isolates collected were
recorded between the months of May to June each year.
These seasonal peaks could be explained by the fact that
in The Gambia this period marks the end of the dry
season. During the dry seasons in the West African belt,
dry and dusty winds damage the mucosa membrane of
the oral cavity [21]. Low absolute humidity and dust
inhibit the mucosal immune defenses by damaging the
mucosal membrane leading to an increased risk of trans-
mission during the dry season. Transmission capacities
of other bacterial pathogens such as Meningococcus
have been reported to be less during the rainy seasons
due to higher humidity [22, 23]. Serotype 5, like most
other serotypes in The Gambia, peaks after the dry and
hot season [15]. Given that Meningococcus and Strepto-
coccus are both transmitted by close contact with
respiratory fluids, assessment of the contribution of low
absolute humidity and dust as risk factors for outbreaks
of S. pneumoniae is of interest in The Gambia.
Antibiotic resistance
All 55 S. pneumoniae serotype 5 isolates were resistant to
co-trimazole. Among these isolates, 44 % (24/55) and
73 % (40/55) were susceptible to tetracycline and oxacillin,
Fig. 2 Clustering of STs from The Gambia by use of the minimum spanning algorithm. Thick, short, solid lines connect single-locus variants; thick,
longer, solid lines connect double-loci variants; Thick, very long, solid lines connect three-loci variants; dash and dotted lines connect four
and five-loci variants respectively. Green portions represent STs identified during the study and red portions represent ST previously
described from the rest of Gambia
Fig. 3 Plot showing temporal trends of serotype 5 and its observed ST’s from 2009–2011 in The Gambia. The x axis represents time in month-year with
the zero point being Jan-09, whilst the y axis represents the number of serotype 5 IPDs recorded. ST 3339 was the prevalent genotype in 2009; ST
3404 peaked at the beginning of 2010 and has since been the dominant genotype for most observed IPD cases of serotype 5 origin
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respectively. Furthermore, 98 % (54/55) of all isolates were
susceptible to chloramphenicol. Observed chlorampheni-
col susceptibility is consistent with a previous study in
The Gambia which showed that all invasive S. Pneumoniae
serotype 1 isolates were susceptible to chloramphenicol.
We however note that susceptibility patterns vary slightly
by serotype with respect to tetracycline, co-trimazole, and
oxacillin [15]. The proportion of serotype 5 isolates suscep-
tible to tetracycline between January 2009 to April 2010
was 0.34 (10/29) while that between May 2010 to August
2011 was 0.62 (16/26). Compared to the period between
January 2009 to April 2010, we found that the number of
isolates susceptible to tetracycline significantly increased
between May 2010 to August 2011 (Pearson chi2 = 0.02,
Fisher’s exact test = 0.03). The same was true for oxacillin
although the increase in susceptibility was not statistically
significant. The proportion of ST 3404 isolates susceptible
to tetracycline and oxacillin was 0.83 (25/30) and 0.97
(29/30), while that for ST 3339 was 0.05 (1/19) and
0.37(7/19), respectively. There is strong evidence that
the number of isolates susceptible to tetracycline and
oxacillin is different for ST 3404 and ST 3339, with
the emerging clone ST3404 showing greater suscepti-
bility. All P-values for both Pearson chi2 and Fisher’s
exact test were < 0.001.
Resistance to 3 or more classes of antibiotics is com-
monly referred to as multiple-antibiotic resistance (MDR)
[24]. About Sixty-one percent (8/13) of all isolates col-
lected in 2009 were resistant to multiple antibiotics, while
30 % (8/27) of all isolates in 2010 and 7 % (1/15) in
2011 were resistant to multiple antibiotics, implying a de-
crease in the prevalence of MDR serotype 5 over time.
Overall, only one ST 3404 isolate showed MDR, suggest-
ing the drop in MDR over time could be attributed to the
emergence of ST 3404. Studies carried out in Canada,
Greece, Sweden and Europe as a whole reveal that
antibiotic resistance patterns are dependent on local
prescribing patterns [25–28]. Drug administration pat-
terns such as dose, route of administration, and dur-
ation of antibiotic regimen also influence antibiotic
resistance [26]. However, the molecular basis of antibiotic
resistance is a major factor to consider since it influences
the likelihood of selection. Resistance requiring the intro-
duction of a gene from a donor species is less likely to
occur than resistance mediated by a single DNA base
change, e.g. pneumococcal resistance to rifampin and
fluoroquinolones [26]. Results from our study are similar
to those from a study in Canada where decline in MDR
19 F, 6B, and 23 F were documented post PCV-7 [11]. The
above study suggested that among other factors, vaccine
pressure could influence changes in antibiotic susceptibility
patterns.
The emergent strain in this study, ST3404, allegedly
showed increased susceptibility to tetracycline, oxacillin,
and consequently penicillin. In The Gambia, oxacillin is
used as an empirical surrogate to penicillin; likewise it is
predictive of reduced penicillin susceptibility [29]. How-
ever, caution must be exercised when using oxacillin disc
diffusion to predict penicillin susceptibility patterns as
predictions can at times be limited by false susceptible
and resistance interpretations [29]. Nonetheless, by reason
of the magnitude of the difference in susceptibility to oxa-
cillin shown by STs 3404 and 3339 (P < 0.001) and the
overall low interpretive error rate of oxacillin disc diffu-
sion [29, 30], ST 3404’s alleged increased susceptibility to
penicillin might be genuine. In light of these results, sur-
veillance to determine if these patterns will change after
the introduction of PCV-13 will be vital to highlight the
role of immunization on susceptibility patterns of various
serotype 5 clones (ST) in The Gambia.
Conclusion, implications and future perspectives
There was an emergence of ST 3404 in The Gambia
prior to the introduction of the PCV-13. Interestingly,
compared to ST 3339, ST 3404 showed lower resistance to
tetracycline and oxacillin. Findings from this study provide
important background data to assess the potential impact
of PCV-13 in routine immunization in The Gambia.
Finally, we recommend a comparative genome study on
STs 3404, 3339 and 289 to better understand differences
antimicrobial sensitivity and virulence, if there be any.
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